Pfizer and Moderna to see higher profits from Covid vaccines
The federal government has agreed to purchase 105 million doses of Pfizer-BioNTech’s rebooted vaccine for $3.2 billion, the Washington Post reported on Friday. At $30.50 a dose, that’s a premium over the initial contracts the government made for the original...
Today it looks more like a bear market rally
In my weekend Saturday Night Quarterback on my subscription JubakAM.com site I said that this week would, probably, answer the question of whether Friday’s big bounce was just a bounce, the start of a buy on the dip rally, or even a bear market rally with a bit...
After news of acquisition Pfizer pops 4.33% on day
Pfizer (PFE) will buy privately held respiratory syncytial virus drug maker ReViral for up to $525 million. Wall Street liked the deal–the stock was up 4.33% today, April 7–because it fits with Pfizer’s RNA virus program–which produced a...
Today’s perfect storm batters stocks
It’s actually surprising that markets aren’t down more so far today. As of noon New York time, the Standard & Poor’s 500 is lower by 1.62% and the Dow Jones Industrial Average is down 1.75%. The NASDAQ Composite has lost 1.65% and the NASDAQ 100...
Watch my new YouTube video: 4 Picks for the Omicron Wave
I’m starting up my videos on JubakAM.com again–this time using YouTube as a platform. My seventy-fifth YouTube video “4 Picks for the Omicron Wave” went up today. Please watch and subscribe to my YouTube channel. And like my video. Here’s...
Please watch my new YouTube Video: Trend of the Week Big Pharma for Safety
I’m starting up my videos again–this time using YouTube as a platform. My sixty-ninth YouTube video “Trend of the Week Big Pharma for Safety” went up today. Please watch and subscribe to my YouTube channel. And like my video. Here’s the...
Publication of FDA review shows Pfizer vaccine almost certain to get emergency use authorization on Thursday
A 53-page review published as a Food & Drug Administration briefing document today confirms that the vaccine from Pfizer (PFE) and BioNTech (BNTX) meets the agency’s standards for emergency use authorization. The briefing document is the result of two weeks...
Pfizer’s warning on logistics difficulty in delivering vaccine stalls stocks at end of trading
Pfizer (PFE) stock tumbled Thursday after the company reportedly slashed its expectations for coronavirus vaccine deliveries in 2020 due to supply-chain issues. “Scaling up the raw material supply chain took longer than expected,” a company spokeswoman...
Why Pfizer’s coronavirus vaccine news is even bigger than it seemed yesterday
There’s really, really good news in Pfizer’s announcement that the coronavirus vaccine it has been developing has turned out to be 90% effective. And that’s true even if it turns out that some other company’s vaccine becomes the preferred...
What we know/don’t know about Pfizer’s coronavirus vaccine
The interim data from Pfizer (PFE) indicated no serious safety concerns, but the data covers a relatively short time period and safety issues could emerge as the company follows trial participants for a longer time. Which is why the U.S. Food & Drug...
Pfizer says it will be ready to file for an emergency use application for its coronavirus vaccine by the third week in November
In a public letter Pfizer (PFE) CEO Albert Bourla wrote that the company hopes to have initial data from its Phase 3 clinical trail of a coronavirus vaccine by the end of October and that it will wait until the third week in November to file an emergency use...
Pfizer to deliver first vaccine efficacy results as soon as September 27–but what, if anything, will they mean?
Pfizer (PFE) and its partner BioNTech (BNTX) plan to take a first look at the efficacy results from their 44,000 personal vaccine trial as soon as September 27. But that first look will be after just 32 coronavirus infections have accumulated in the two...
Good vaccine news from Oxford/AstraZeneca–and others today
With 160 coronavirus vaccine candidates under development around the world, it’s not surprising that we would get reports on three successful, if very early, trials today. The coronavirus vaccine that Oxford University is developing with AstraZeneca (AZN) showed...
Pfizer good news on coronavirus vaccine moves stocks ahead
Just in case you were wondering if the market is counting on a coronavirus vaccine in the nearer term, wonder no longer. (Expectations, for the moment, look to a vaccine by January, if I can judge by comments I’m seeing.) News from Pfizer (PFE) and partner...
Selling Pfizer out of my Dividend Portfolio tomorrow on Dem’s proposed drug-pricing bill
Why introduce legislation that will dead on arrival in the Republican controlled Senate? Because House Speaker Nancy Pelosi and other Democrats know that controlling drug prices is extremely popular with voters. And a proposal that is a serious effort to lower drug...
Government action on drug prices seems far, far away
The format was familiar: Seven CEOs sit in front of a Senate Committee probing their industry’s business practices. But whereas a Congressional hearing a decade ago marked a key moment in what was a costly public reckoning for the tobacco industry, today’s...
Buying Pfizer for my Dividend Portfolio
I’m going to take advantage of the selling in the market in general and in the drug sector in particular–on news of the asbestos liability at Johnson & Johnson and fears of the death of Obamacare (AKA the Affordable Care Act)–to buy Pfizer (PFE) in my Dividend...
Shares of Jubak Pick Acadia Pharmaceuticals pop 11% on buyout rumors
Update January 4. Shares of Acadia Pharmaceuticals (ACAD) were up 12% this morning, January 4, before closing with a gain of 11.02% to $31.94. The action came on rumors that Pfizer (PFE) or another big drug company would make a bid for the biotech on the strength of...
So much for the post-Trump-victory drug stock rally
“I’m going to bring down drug prices. I don’t like what’s happened with drug prices,” President-elect Donald Trump said in an interview with Time posted on the magazine’s website today. So much, the stock market has concluded today, for the idea that a President...Jim’s Daily Email Alerts:
Every post from Jubak Picks straight to your mailbox. And they're free!